Given the critical role and clinical relevance of CCL20-modulated PMN-MDSCs on promoting stemness of breast cancer cells, we sought to evaluate whether targeting CXCL2-CXCR2 axis could be an effective strategy to treat CCL20high-expressing breast cancer patients who are prone to show poor response to DTX. This evidence concerns the gene CXCL2 and breast cancer.